Researcher’s Curriculum Vitae
PERIKLIS PAPPAS
Personal
Born June 28, 1965, Ioannina, Greece. Married; three children.
Employment
 January-February 1992; Research Fellow at the “Catherine Griffiths Cancer
Research Laboratory” of the Medical Oncology Unit of Westminster Hospital
(MTT and other clonogenic assays).
 June-August 1996; Research Fellow (two months) at the Department of
Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health
Sciences Center, Denver, USA (Tissue-specific expression of rat ALDH3 gene).
 August-September 2000; Research Fellow (two weeks) at the Toxicology
Research Unit, Medical School, University of Tampere, CIMO Tampere, Finland
(Isolation, collection and culturing Muller cells and other retinal cells).
 1998 – 2004; Elected Lecturer in Pharmacology, Medical School, University of
Ioannina.
 2004 – presence; Elected Assistant Professor in Pharmacology, Medical School,
University of Ioannina.
Teaching
 1998-presence: Medical School, University of Ioannina. 3rd year’s students.
“Medical Pharmacology”, “Basic Pharmacokinetics”, “Toxicology”.
 2000-2003: Department of Biochemistry, University of Ioannina. 3rd year’s
students “Biochemical and Molecular Pharmacology”,
 2003-2008: University of Ioannina. Post-graduate Program of Certification on
Agricultural Products’ Quality, “Quality and Environment – II”.
 2006-presence: Department of Biological Applications and Technology,
University of Ioannina. 4th year’s students. “Biochemical and Molecular
Toxicology”.
Participation in International Congresses (last 10 years)

4th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, 1216 April, 2000, Antalya, Turkey.

10th International Workshop of Enzymology and Molecular Biology of
Carbonyl Metabolism, July 1-5, 2000, Taos, New Mexico, USA.

39th Congress of the European Society of Toxicology, September 13-16, 2001,
Istanbul, Turkey.

5th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, May
29 – June 1, 2002, Constanta, Romania.

11th International Workshop of Enzymology and Molecular Biology of
Carbonyl Metabolism, July 2-7, 2002, Ystad, Sweden.

European Congress on Biomedical Research of Alcoholism, September 11-14,
2003, Prague, Czech Republic.

International Course on Pharmacokinetic-Pharmacodynamic Modelling
Concepts and Applications, Leiden/Amsterdam Center for Drug Research
October 12-15, 2003, Leiden/Amsterdam, The Netherlands.
1

16th International Congress on Anticancer Treatment, February 1–4, 2004,
Paris, France.

Intermediate Level Workshop on Pharmacokinetic/Pharmacodynamic Data
Analysis: A Hands-on Course Using WinNonlin, September 20–23, 2004,
Nice, France.

13th European Cancer Conference, 30 October – 3 November 2005, Paris,
France.

18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer
Therapeutics”, November 7-10, 2006, Prague, Czech Republic.

Targeting Protein-Protein Interactions: Design Principles and Therapeutic
Value, July 14-15, 2007, Kuopio, Finland.

20th Meeting of the European Association for Cancer Research (EACR), 5-8
July 2008, Lyon, France.

33rd European Society for Medical Oncology Congress, September 12-16,
2008, Stockholm, Sweden.

7th International Symposium on Targeted Anticancer Therapies (TAT),
March 23-25, 2009, Amsterdam, The Netherlands.

39th Annual European Society for Dermatological Research (ESDR) Meeting,
9-12 September 2009, Budapest, Hungary.

21st Meeting of the European Association for Cancer Research (EACR), 26-29
June 2010, Oslo, Norway.

40th Annual European Society for Dermatological Research (ESDR) Meeting,
8-11 September 2010, Helsinki, Finland.
Scientific Award: Data Base for personal PC, with all the drugs of the Greek market.
Member of Scientific Societies
Member of Organizing Committees
Techniques: gDNA, mRNA, cDNA, qRT-PCR, western blotting, design of primers,
migration and wound healing assays, cloning, transfection and reporter assays, in vitro
activation, confocal microscope, in vitro cytotoxicity tests (WST-1, MTS assays),
mutagenicity, cell culturing, primary and stable cancer cell lines, isolation of human
endothelial cells (HUVEC), nuclear – cytosolic – microsomal extracts, drug levels –
pharmacokinetics in biological fluids (HPLC, atomic absorption spectroscopy, gass
chromatography, GCMS), ELISA, RIA. Animal handling.
Participation in Research Grants
 1992-1994; Research Fellow in: “Cell Injury and Defense Mechanisms” as part of
the EC's program “STRIDE Hellas”.
 1996-1999: Principal investigator in: “Phenobarbital mechanism of action in two
genetically modified rat substrains”, funded by the Greek Ministry of
Infrastructure, Research & Technology.
 1997-2000: Principal investigator in: “In vitro Oculotoxicity – BIOMED II”,
supported by EU funds.
2


2005-2007: “Study on the effects of specific COX-2 inhibitors on CNS of rats”,
supported by the Greek Ministry of Infrastructure (60,000 euro).
2006-2008: “Drug metabolizing protein expressions in brain tumors. Resistance in
chemotherapy and prognostic markers” funded by the Greek Ministry of Health
(15,000 euro).
Personal Funded Grants
 “Biochemical parameters of the skin and sun radiation. Possible toxicity
markers of UV radiation of the skin”. Research Committee of UoI 2001-2002
(5,870 euro).
 “Corneal, pterygium and retinal biochemical parameters. Evaluation of ocular
drug toxicity with in vitro techniques” Greek Ministry of Health 2001-2003
(7,340 euro).
 “Regulation of aldehyde dehydrogenases by the nuclear receptors CAR and
PXR in Wistar rats genetically selected for phenobarbital inducibility”
Heraklitos 2010-2013 (45,000 euro).
PUBLICATIONS
Full papers: 32
Citations: 220
Abstracts
A. Published
1. Karageorgou M, Vasiliou V, Pappas Ρ, Marselos M: Enhancement of aldehyde
dehydrogenase activity by diethylstylbestrol in the liver of Wistar rat. Ρharmacology
& Τoxicology 67, Suppl 1, Ρ22, 1990.
2. Marselos M, Vasiliou V, Kafetzopoulos Ε, Pappas Ρ: Differential response to
centrally acting drugs between two rat substrains selected for the inducibility of
aldehyde dehydrogenase in the liver. Ρharmacology & Τoxicology 67, Suppl 1, Ρ23,
1990.
3. Ρappas Ρ, Stephanou Ρ, Vasiliou V, Marselos Μ: Drug metabolism in the rat liver
after exposure to α pyrogenic inflammatory agent. Ρharmacological Research 31,
Suppl 1, 49, 1995.
4. Marselos M, Ρappas Ρ, Stephanou Ρ, Vasiliou V: Different biochemical and
pharmacological responses in two substrains of the Wistar rat. Ρharmacological
Research 31, Suppl 1, 171, 1995.
5. Pappas P, Stephanou P, Vasiliou V and Marselos M: Genetic differences in
phenobarbital inducibility of two rat substrains. Fundamental & Clinical
Pharmacology 13, Suppl 1, 1999.
6. Pappas P, Karamanakos PN, Gousia P, Marselos M: Time-response effects of LPS
on several neuro-biochemical parameters of rat liver and brain. Toxicol Letters, 123,
Suppl 1, 63, 2001.
7. Gousia P, Pappas P, Karamanakos PN, Marselos M, Hatzinikolaou DG,
Psallidopoulos M, Stavridou A: CNS effects in the rat of alcoholic beverages exposed
to electromagnetic radiation. Toxicol Letters, 123, Suppl 1, 64, 2001.
3
8. Mannerstrom M, Zorn-Kruppa M, Toimela M, Maenpaa H, Salminen L, Pappas P,
Tahti H: The cytotoxicity of selected systemic and eye drugs in retinal pigment
epithelial cell cultures. Toxicol Letters, 123, Suppl 1, 104, 2001.
9. Karamanakos PN, Pappas P, Marselos M: Disulfiram-like effects of commonly
prescribed antibiotic agents. Toxicol Letters, 123, Suppl 1, 105, 2001.
10. Pappas P, Yfanti F, Karamanakos PN, Nikolaidou M, Marselos M: Neurochemical
changes of D-glucuronolactone in Wistar rat brain. Alcohol and Alcoholism 2003,
38(5).
11. Briasoulis E, Tolis C, Pappas P, Marselos M, Nicolaides C, Nikiforidis L,
Nikolaidou M, Siarabi O, Tzamakou E, Pavlidis N: Metronomic oral vinorelbine
(MOVIN): a dose establishing translational and pharmacokinetic study in patients
with metastatic refractory cancer. European Journal of Cancer Supplements 2005,
3(2):422.
12. Pentheroudakis G, Golfinopoulos V, Karina M, Pappas P, Nikiforidis L,
Nicolaidou M, Tzamakou E, Marselos M, Fountzilas G, Pavlidis N: Weekday on weekend off oral capecitabine: a Phase I study of a continuous schedule better
simulating protracted fluoropyrimidine therapy. European Journal of Cancer
Supplements 2005, 3(2):422.
13. Pappas P, Biziota E, Marselos M, Briasoulis E. Evaluation of antiproliferative and
molecular effects of vinorelbine and its active metabolite 4-O-deacetyl-vinorelbine on
human endothelial cells in an in vitro simulation model of metronomic chemotherapy.
European Journal of Cancer Supplements 2008, 6(9):138.
14. Briasoulis E, Kalofonos H, Samantas E, Varthalitis I, Syrigos KN, Fountzilas G,
Pappas P, Sainis I, Puozzo C, Pavlidis N. Metronomic oral vinorelbine in patients
with recurrent breast, prostate or non-small cell lung cancer: optimal dose-finding trial
of the hellenic cooperative oncology group. Annals of Oncology 2008, 19(S8):163.
15. Pappas P, Biziota E, Marselos M, Briasoulis E. Low dose metronomic treatment
elicits the anti-angiogenic profile of vinorelbine in an in vitro model of human
endothelial cells. Annals of Oncology 2009, 20(S3):32.
16. Gaitanis G, Pappas P, Magiatis P, Mexia N, Galanou M, Stathopoulou K,
Skaltsounis AL, Marselos M, Velegraki A, Bassukas ID. The seborrheic dermatitis
associated Malassezia indoles induce the Aryl-hydrocarbon receptor (AhR) dependent
genes in HaCaT cells. Journal of Investigative Dermatology 2009, 129:105.
17. Biziota E, Briasoulis E, Mavroeidis L, Marselos M, Pappas P. PPARg agonist
rosiglitazone enhances the antiproliferative and anti-angiogenic profile of metronomic
vinorelbine chemotherapy. European Journal of Cancer 2010, 8(5):72.
19. Gaitanis G, Galanou M, Magiatis P, Mexia N, Stathopoulou K, Skaltsounis A-L,
Marselos M, Velegraki A, Bassukas ID, Pappas P. Malassezia Metabolites indirubin
and malassezin are potent activators of the Aryl-hydrocarbon receptor (AhR) in
HaCaT cells. Journal of Investigative Dermatology 2010, 130(S2):91.
B. In Proceedings
(More than 50).
4
Full Papers
1. Pappas P, Vasiliou V, Nebert DW, Marselos M. Responses of rat liver cytosolic
aldehyde dehydrogenase to toxic chemicals, glutathione depletion, and other forms of
stress. Biochem Pharmacol. 1994, 48:841-845.
2. Pappas P, Vasiliou V, Karageorgou M, Stefanou P, Marselos M. Studies on the
induction of rat class 3 aldehyde dehydrogenase. Adv Exp Med Biol. 1995, 372:143149.
3. Pappas P, Stephanou P, Karamanakos P, Vasiliou V, Marselos M. Ontogenesis and
expression of ALDH activity in the skin and the eye of the rat. Adv Exp Med Biol.
1997, 414:73-80.
4. Konstandi M, Pappas P, Johnson E, Lecklin A, Karageorgou M, Marselos M.
Modification of reproductive function in the rat by 3-methylcholanthrene. Pharmacol
Res. 1997, 35:107-111.
5. Konstandi M, Pappas P, Johnson E, Lecklin A, Marselos M. Suppression of the
acquisition of conditioned avoidance behavior in the rat by 3-methylcholanthrene.
Pharmacol Biochem Behav. 1997, 56:637-641.
6. Pappas P, Stephanou P, Vasiliou V, Marselos M. Anti-Inflammatory agents and
inducibility of hepatic drug metabolism. Eur J Drug Metab Pharmacokinet. 1998,
23:457-460.
7. Pappas P, Stephanou P, Vasiliou V, Marselos M. Zoxazolamine paralysis in two
substrains - Differences of hepatic drug metabolism. Eur J Drug Metab
Pharmacokinet. 1998, 23:461-467.
8. Stephanou P, Konstandi M, Pappas P, Marselos M. Alterations in central
monoaminergic neurotransmission induced by polycyclic aromatic hydrocarbons in
rats. Eur J Drug Metab Pharmacokinet. 1998, 23:475-481.
9. Stephanou P, Pappas P, Vasiliou V, Marselos M. Prepubertal regulation of the rat
dioxin-inducible aldehyde dehydrogenase. Adv Exp Med Biol. 1999, 463:143-150.
10. Pappas P, Stephanou P, Sotiropoulou M, Murphy C, Salminen L, Marselos M.
Effects of tamoxifen and toremifene on ALDH1 and ALDH3 in human retinal
pigment epithelial cells and rat liver. Adv Exp Med Biol. 1999, 463:151-158.
11. Sotiropoulou M, Pappas P, Marselos M. Effects of 3-methylcholanthrene and
aspirin co-administration on ALDH3A1 in HepG2 cells. Chem Biol Interact. 2001,
130-132:235-245.
12. Pappas P, Stephanou P, Karamanakos P, Vasiliou V, Marselos M. Phenobarbital
inducibility and differences in protein expression of an animal model. Chem Biol
Interact. 2001, 130-132:275-283.
13. Karamanakos P, Pappas P, Stephanou P, Marselos M. Differentiation of
disulfiram effects on central catecholamines and hepatic ethanol metabolism.
Pharmacol Toxicol. 2001, 88:106-110.
14. Mannerstrom M, Zorn-Kruppa M, Diehl H, Engelke M, Toimela T, Maenpaa H,
Huhtala A, Uusitalo H, Salminen L, Pappas P, Marselos M, Mantyla M, Mantyla
E,Tahti H. Evaluation of the cytotoxicity of selected systemic and intravitreally dosed
drugs in the cultures of human retinal pigment epithelial cell line and of pig primary
retinal pigment epithelial cells. Toxicol In Vitro. 2002, 16:193-200.
5
15. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K,
Androulakis N, Souglakos J, Vardakis N, Nikolaidou M., Samonis G, Marselos M.
Georgoulias V. A dose-escalation and pharmacokinetic study of gemcitabine and
oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003, 14:304-312.
16. Pappas P, Sotiropoulou M, Karamanakos P, Kostoula A, Levidiotou St, Marselos
M. Acute phase response to benzo[α]pyrene and induction of rat ALDH3A1. Chem
Biol Interact. 2003, 143-144:55-62.
17. Huhtala A, Alajuuma P, Burgalassi S, Chetoni P, Diehl H, Engelke M, Marselos
M, Monti D, Pappas P, Saettone MF, Salminen L, Sotiropoulou M, Tahti H, Uusitalo
H, Zorn-Kruppa M. A collaborative evaluation of the cytotoxicity of two surfactants
by using the human corneal epithelial cell line and the WST-1 test. J Ocul Pharmacol
Ther. 2003, 19:11-21.
18. Karamanakos PN, Pappas P, Marselos M. Involvement of the brain serotonergic
system in the locomotor stimulant effects of chlorpheniramine in Wistar rats:
implication of postsynaptic 5-HT1A receptors. Behav Brain Res. 2004, 148:199-208.
19. Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics
of Imatinib Mesylate in End Stage Renal Disease. A case study. Cancer Chemother
Pharmacol. 2005, 56(4):358-360.
20. Pappas P, Mavroudis D, Nikolaidou M, Georgoulias V, Marselos M. Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine.
Anticancer Drugs. 2006, 17(10):1185-91.
21. Mitsou K, Koulianou A, Lambropoulou D, Pappas P, Albanis T, Lekka M.
Growth rate effects, responses of antioxidant enzymes and metabolic fate of the
herbicide Propanil in the aquatic plant Lemna minor. Chemosphere. 2006, 62(2):27584.
22. Pentheroudakis G, Pappas P, Golfinopoulos V, Fountzilas G, Nikolaidou M,
Boumba VA, Vougiouklakis T, Nikiforidis L, Tzamakou E, Siarabi O, Marselos M,
Pavlidis N. Weekday on-weekend off oral capecitabine: a phase I study of a
continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer
Chemother Pharmacol. 2007, 60(5):733-9.
23. Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A,
Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D.
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal
doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Br J
Cancer. 2007, 2;97(1):43-9.
24. Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis
T, Marselos M. Pharmaceutical agents known to produce disulfiram-like reaction:
effects on hepatic ethanol metabolism and brain monoamines. Int J Toxicol. 2007,
26(5):423-32.
25. Karamanakos PN, Pappas P, Marselos M. Comment on "Disulfiram-like effect of
cyproterone acetate" [Z. Nitzan, M. Dan, Eur. J. Obstet. Gynecol. Reprod. Biol.
(2007)]. Eur J Obstet Gynecol Reprod Biol. 2009, 146(2):237.
26. Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N,
Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. A dose escalation and
pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and
6
oxaliplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol.
2008, 62(3):449-56.
27. Karamanakos PN, Pappas P, Marselos M. Possible role for chlorpheniramine in
the treatment of L-DOPA induced dyskinesia in Parkinson's disease. Pharm World
Sci. 2008, 30(1):1-2.
28. Karamanakos PN, Pappas P, Marselos M. Disulfiram neuropathy: two cases of
distal axonopathy. Clin Toxicol (Phila). 2008, 46(9):917-8.
29. Froudarakis ME, Pataka A, Pappas P, Anevlavis S, Argiana E, Nikolaidou M,
Kouliatis G, Pozova S, Marselos M, Bouros D. Phase 1 trial of lipoplatin and
gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung
carcinoma. Cancer. 2008, 113(10):2752-60.
30. Karamanakos PN, Trafalis DT, Geromichalos GD, Pappas P, Harkitis P,
Konstandi M, Marselos M. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular
modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1butanone (NNK)-induced mutagenicity. Arch Toxicol. 2009, 83(6):571-80.
31. Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A,
Marselos M, Georgoulias V, Mavroudis D. A dose escalation and pharmacokinetic
study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in
patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009, 65(1):1218.
32. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M,
Pavlidis N. Dose-ranging study of metronomic oral vinorelbine in patients with
advanced refractory cancer. Clin Cancer Res. 2009, 15(20):6454-61.
7